Main Article Content
Myeloid and lymphoid neoplasms with eosinophilia and PDGFRA rearrangements are recognized as a distinct entity within the section of “Myeloid/Lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK)”. Based on the WHO classification of tumors of Hematopoietic and Lymphoid tissues (5th Ed, 2022), these neoplasms also comprise of PDGFRB rearrangement, FGFR1 gene rearrangements, JAK2 rearrangement, FLT3 rearrangement, ETV6::ABL1 fusion as well as some others. Of note, these are recently defined entities and are still evolving. In this chapter, practical issues regarding diagnosis, cytogenetic testing, molecular studies, therapeutics, and clinical implications are discussed. Differential diagnosis in consideration for eosinophilia and hypereosinophilic syndrome are further highlighted.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.